Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.

Cao J, Zhu Z, Wang H, Nichols TC, Lui GYL, Deng S, Rejto PA, VanArsdale T, Hardwick JS, Weinrich SL, Wei P.

Oncogene. 2019 May;38(21):4125-4141. doi: 10.1038/s41388-019-0708-7. Epub 2019 Jan 30.

PMID:
30700828
2.

Epigenetic Modifications of Cytosine: Biophysical Properties, Regulation, and Function in Mammalian DNA.

Hardwick JS, Lane AN, Brown T.

Bioessays. 2018 Mar;40(3). doi: 10.1002/bies.201700199. Epub 2018 Jan 25. Review.

PMID:
29369386
3.

Creating space for relationships.

Maataoui SL, Hardwick JS, Lundquist TS.

Psychol Serv. 2017 Aug;14(3):347-351. doi: 10.1037/ser0000179.

PMID:
28805419
4.

Stoichiometry and Dispersity of DNA Nanostructures Using Photobleaching Pair-Correlation Analysis.

Hariri AA, Hamblin GD, Hardwick JS, Godin R, Desjardins JF, Wiseman PW, Sleiman HF, Cosa G.

Bioconjug Chem. 2017 Sep 20;28(9):2340-2349. doi: 10.1021/acs.bioconjchem.7b00369. Epub 2017 Aug 22.

PMID:
28777539
5.

5-Formylcytosine does not change the global structure of DNA.

Hardwick JS, Ptchelkine D, El-Sagheer AH, Tear I, Singleton D, Phillips SEV, Lane AN, Brown T.

Nat Struct Mol Biol. 2017 Jun;24(6):544-552. doi: 10.1038/nsmb.3411. Epub 2017 May 15.

6.

An accessible pharmacodynamic transcriptional biomarker for notch target engagement.

Tanis KQ, Podtelezhnikov AA, Blackman SC, Hing J, Railkar RA, Lunceford J, Klappenbach JA, Wei B, Harman A, Camargo LM, Shah S, Finney EM, Hardwick JS, Loboda A, Watters J, Bergstrom DA, Demuth T, Herman GA, Strack PR, Iannone R.

Clin Pharmacol Ther. 2016 Apr;99(4):370-80. doi: 10.1002/cpt.335. Epub 2016 Feb 17.

PMID:
26765077
7.

Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.

Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, Seo A, Koelle DM, Madeleine M, Bhatia S, Nakajima H, Sano S, Hardwick JS, Disis ML, Cleary MA, Becker JC, Nghiem P.

Cancer Immunol Res. 2014 Nov;2(11):1071-9. doi: 10.1158/2326-6066.CIR-14-0005. Epub 2014 Aug 12.

8.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24. doi: 10.1016/j.clml.2012.07.007.

PMID:
23040438
9.

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.

Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C.

Leuk Lymphoma. 2012 Aug;53(8):1501-8. doi: 10.3109/10428194.2012.656625. Epub 2012 Feb 13.

PMID:
22239668
10.

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J.

Clin Cancer Res. 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. Epub 2011 Aug 2.

11.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J.

J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.

PMID:
21383291
12.

A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gastroenterology. 2010 Dec;139(6):1995-2004.e15. doi: 10.1053/j.gastro.2010.05.080. Epub 2010 Jun 2.

PMID:
20621683
13.

Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2177-82. doi: 10.1073/pnas.0909797107. Epub 2010 Jan 13.

14.

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

Fujiwara Y, Yamamoto N, Yamada Y, Yamada K, Otsuki T, Kanazu S, Iwasa T, Hardwick JS, Tamura T.

Cancer Sci. 2009 Sep;100(9):1728-34. doi: 10.1111/j.1349-7006.2009.01237.x. Epub 2009 May 31.

15.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ.

Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.

PMID:
19568773
16.

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG.

Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24.

17.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC.

J Clin Oncol. 2009 Apr 20;27(12):2052-8. doi: 10.1200/JCO.2008.19.0694. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262-3.

18.

Development of vorinostat: current applications and future perspectives for cancer therapy.

Richon VM, Garcia-Vargas J, Hardwick JS.

Cancer Lett. 2009 Aug 8;280(2):201-10. doi: 10.1016/j.canlet.2009.01.002. Epub 2009 Jan 31. Review.

PMID:
19181442
19.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

PMID:
17962510
20.

Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling.

Hardwick JS, Yang Y, Zhang C, Shi B, McFall R, Koury EJ, Hill SL, Dai H, Wasserman R, Phillips RL, Weinstein EJ, Kohl NE, Severino ME, Lamb JR, Sepp-Lorenzino L.

Mol Cancer Ther. 2005 Mar;4(3):413-25.

21.

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins.

Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14866-70.

22.

Activation of the lck tyrosine-protein kinase by the binding of the tip protein of herpesvirus saimiri in the absence of regulatory tyrosine phosphorylation.

Hartley DA, Hurley TR, Hardwick JS, Lund TC, Medveczky PG, Sefton BM.

J Biol Chem. 1999 Jul 16;274(29):20056-9.

23.

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

Peterson RT, Desai BN, Hardwick JS, Schreiber SL.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4438-42.

25.

Stimulation of phosphorylation of Tyr394 by hydrogen peroxide reactivates biologically inactive, non-membrane-bound forms of Lck.

Yurchak LK, Hardwick JS, Amrein K, Pierno K, Sefton BM.

J Biol Chem. 1996 May 24;271(21):12549-54.

26.

Supplemental Content

Loading ...
Support Center